NO20051669L - Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner - Google Patents

Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner

Info

Publication number
NO20051669L
NO20051669L NO20051669A NO20051669A NO20051669L NO 20051669 L NO20051669 L NO 20051669L NO 20051669 A NO20051669 A NO 20051669A NO 20051669 A NO20051669 A NO 20051669A NO 20051669 L NO20051669 L NO 20051669L
Authority
NO
Norway
Prior art keywords
treatment
reagents
diseases
methods
disorders associated
Prior art date
Application number
NO20051669A
Other languages
English (en)
Norwegian (no)
Inventor
Curtis Keith
Jason Fong
Palaniyandi Manivasakam
James M Nichols
Grant R Zimmermann
Daniel Grau
Brendan Smith
Benjamin A Auspitz
Bradley B Brasher
Noah Sachs
Todd W Chappell
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051669(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20051669L publication Critical patent/NO20051669L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
NO20051669A 2002-09-24 2005-04-04 Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner NO20051669L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23
PCT/US2003/030156 WO2004030618A2 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Publications (1)

Publication Number Publication Date
NO20051669L true NO20051669L (no) 2005-06-10

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051669A NO20051669L (no) 2002-09-24 2005-04-04 Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner

Country Status (12)

Country Link
EP (1) EP1553955A4 (is)
JP (1) JP2006503905A (is)
AR (1) AR041386A1 (is)
AU (1) AU2003299196A1 (is)
BR (1) BR0314713A (is)
CA (1) CA2509526A1 (is)
HR (1) HRP20050355A2 (is)
IS (1) IS7811A (is)
MX (1) MXPA05003152A (is)
NO (1) NO20051669L (is)
TW (1) TW200422042A (is)
WO (1) WO2004030618A2 (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS
BRPI0511272A (pt) * 2004-05-17 2007-12-04 Combinatorx Inc métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CN101203214B (zh) * 2005-04-13 2012-11-21 艾升制药公司 用于治疗皮肤结缔组织疾病的β2-肾上腺素受体激动剂
JP4832806B2 (ja) * 2005-06-03 2011-12-07 久光製薬株式会社 経皮投与製剤
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CN101568331A (zh) * 2006-09-08 2009-10-28 奥尔制药有限公司 减少或缓解消化道炎症的方法
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
PT117765B (pt) * 2022-01-28 2025-04-04 Faculdade De Farmacia Da Univ De Lisboa Formulação tópica de fluvoxamina para o tratamento de psoríase
TW202423434A (zh) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 mTOR抑制劑的點眼劑微懸液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
ES2227707T3 (es) * 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
EP1553955A4 (en) 2008-11-05
MXPA05003152A (es) 2006-04-27
JP2006503905A (ja) 2006-02-02
WO2004030618A3 (en) 2005-04-07
TW200422042A (en) 2004-11-01
AR041386A1 (es) 2005-05-18
IS7811A (is) 2005-04-19
HRP20050355A2 (en) 2005-10-31
AU2003299196A1 (en) 2004-04-23
BR0314713A (pt) 2005-07-26
WO2004030618A2 (en) 2004-04-15
CA2509526A1 (en) 2004-04-15
EP1553955A2 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
NO20053678L (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
NO20051669L (no) Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner
Erdes et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20035473D0 (no) Oralt administrerte doseringsformer av GABA-analogprodrugs som har reduserttoksisitet
Chang et al. Medial prefrontal cortex activation facilitates re-extinction of fear in rats
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JP2017528483A5 (is)
Ali et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
Allen-Philbey et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
NO20062363L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrrelser
ZA200604253B (en) Methods and reagents for the treatment of inflammatory disorders
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
WO2007139753A3 (en) Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
MX2025014320A (es) Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
NO20064964L (no) Behandling av svekket respiratorisk funksjon
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
WO2006138372A3 (en) Methods and reagents for the treatment of inflammatory disorders
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
MX2022002612A (es) Composiciones de il-22 orales, intrarrectales u otras relacionadas con el intestino y metodos de uso de las mismas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application